PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Co-dydramol 20/500 - Pain
PAD Profile : Co-dydramol 20/500 - Pain
Keywords :
Dihydrocodeine with paracetamol, non-opioid analgesia, analgesics, compound analgesics
Traffic Light Status
Status 1 of 1.
Status :
Non Formulary
Important
Formulations :
- Tablets
Important Information :
Fixed combinations are less preferred.
The MHRA advises when prescribing dihydrocodeine with paracetamol, the tablet strength and dose must be clearly indicated
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Oxycodone
- Co-codamol (Codeine phosphate/paracetamol)
- Tramadol hydrochloride
- Oxycodone hydrochloride/naloxone hydrochloride
- Fentanyl
- Tramadol hydrochloride
- Tramadol hydrochloride
- Paracetamol
- Codeine phosphate
- Dihydrocodeine tartrate
- Buprenorphine
- Morphine sulfate
- Pregabalin
- Gabapentin
- Dronabinol/cannabidiol
- Co-dydramol (Dihydrocodeine/paracetamol)
- Ibuprofen
- Meptazinol hydrochloride
- Pethidine hydrochloride
- Diamorphine hydrochloride
- Alfentanil hydrochloride
- Co-dydramol (Dihydrocodeine/paracetamol)
- Nefopam hydrochloride
- Papaveretum
- Aspirin
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
Associated BNF Codes
04. Central Nervous System
04.07.01. Non-opioid analgesics and compound preparations